Contineum Therapeutics (CTNM) Accumulated Expenses (2023 - 2026)

Contineum Therapeutics' Accumulated Expenses history runs 4 years deep, the most recent figure standing at $3.6 million for Q2 2026.

• In Q2 2026, Accumulated Expenses fell 3.18% year-over-year to $3.6 million; the TTM figure through Jun 2026 stood at $3.6 million (down 3.18% YoY), while the FY2025 annual figure was $6.4 million, down 4.83% from the prior year.
• Accumulated Expenses for Q2 2026 stood at $3.6 million, up from $2.9 million in the prior quarter.
• The five-year high for Accumulated Expenses was $6.7 million in Q4 2024, with the low at $2.5 million in Q2 2024.
• The 4-year median for Accumulated Expenses is $3.8 million (2025), against an average of $4.3 million.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses surged 53.04% in 2024, then retreated 25.84% in 2025.
• Contineum Therapeutics' Accumulated Expenses stood at $4.4 million in 2023, then soared by 53.04% to $6.7 million in 2024, then dropped by 4.83% to $6.4 million in 2025, then slumped by 43.2% to $3.6 million in 2026.
• Business Quant data shows CTNM's Accumulated Expenses at $3.6 million in Q2 2026, $2.9 million in Q1 2026, and $6.4 million in Q4 2025.